{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T19:24:54Z","timestamp":1792783494597,"version":"4.5.0"},"reference-count":132,"publisher":"Springer Science and Business Media LLC","issue":"6","license":[{"start":{"date-parts":[[2017,2,7]],"date-time":"2017-02-07T00:00:00Z","timestamp":1486425600000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"Ipsen, Novartis and Pfizer"},{"name":"Pfizer, Novartis and Ipsen"},{"name":"Pfizer, Novartis and Ipsen"},{"name":"Pfizer and Novartis"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Endocrinol Invest"],"published-print":{"date-parts":[[2017,6]]},"DOI":"10.1007\/s40618-017-0614-1","type":"journal-article","created":{"date-parts":[[2017,2,7]],"date-time":"2017-02-07T13:36:00Z","timestamp":1486474560000},"page":"577-589","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":74,"title":["Pegvisomant in acromegaly: an update"],"prefix":"10.1007","volume":"40","author":[{"given":"A.","family":"Giustina","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"G.","family":"Arnaldi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"F.","family":"Bogazzi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S.","family":"Cannav\u00f2","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.","family":"Colao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"L.","family":"De Marinis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"E.","family":"De Menis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"E.","family":"Degli Uberti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"F.","family":"Giorgino","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S.","family":"Grottoli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A. G.","family":"Lania","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"P.","family":"Maffei","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"R.","family":"Pivonello","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"E.","family":"Ghigo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2017,2,7]]},"reference":[{"key":"614_CR1","doi-asserted-by":"crossref","first-page":"3933","DOI":"10.1210\/jc.2014-2700","volume":"99","author":"L Katznelson","year":"2014","unstructured":"Katznelson L, Laws ER, Melmed S et al (2014) Acromegaly: an endocrine society clinical practice guideline. J Clin Endocrinol Metab 99:3933\u20133951","journal-title":"J Clin Endocrinol Metab"},{"key":"614_CR2","doi-asserted-by":"crossref","first-page":"3141","DOI":"10.1210\/jc.2009-2670","volume":"95","author":"A Giustina","year":"2010","unstructured":"Giustina A, Chanson P, Bronstein MD et al (2010) Acromegaly consensus group. A consensus on criteria for cure of acromegaly. J Clin Endocrinol Metab 95:3141\u20133148","journal-title":"J Clin Endocrinol Metab"},{"issue":"5","key":"614_CR3","doi-asserted-by":"crossref","first-page":"1509","DOI":"10.1210\/jc.2008-2421","volume":"4","author":"S Melmed","year":"2009","unstructured":"Melmed S, Colao A, Barkan A et al (2009) Acromegaly consensus group. Guidelines for acromegaly management: an update. J Clin Endocrinol Metab 4(5):1509\u20131517","journal-title":"J Clin Endocrinol Metab"},{"issue":"17","key":"614_CR4","doi-asserted-by":"crossref","first-page":"2433","DOI":"10.1517\/14656566.2013.847090","volume":"14","author":"A Giustina","year":"2013","unstructured":"Giustina A, Karamouzis I, Patelli I, Mazziotti G (2013) Octreotide for acromegaly treatment: a reappraisal. Expert Opin Pharmacother 14(17):2433\u20132447","journal-title":"Expert Opin Pharmacother"},{"issue":"5","key":"614_CR5","doi-asserted-by":"crossref","first-page":"e36411","DOI":"10.1371\/journal.pone.0036411","volume":"7","author":"A Giustina","year":"2012","unstructured":"Giustina A, Mazziotti G, Torri V, Spinello M, Floriani I, Melmed S (2012) Meta-analysis on the effects of octreotide on tumor mass in acromegaly. PLoS One 7(5):e36411","journal-title":"PLoS One"},{"issue":"3","key":"614_CR6","doi-asserted-by":"crossref","first-page":"791","DOI":"10.1210\/jc.2013-2480","volume":"99","author":"A Colao","year":"2014","unstructured":"Colao A, Bronstein MD, Freda P et al (2014) Pasireotide versus octreotide in acromegaly: a head-to-head superiority study. J Clin Endocrinol Metab 99(3):791\u2013799","journal-title":"J Clin Endocrinol Metab"},{"key":"614_CR7","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1007\/s11102-014-0585-6","volume":"18","author":"M Sheppard","year":"2014","unstructured":"Sheppard M, Bronstein MD, Freda P et al (2014) Pasireotide LAR maintains inhibition of GH and IGF-1 in patients with acromegaly for up to 25 months: results from the blinded extension phase of a randomized, double-blind, multicenter, phase III study. Pituitary 18:385\u2013394","journal-title":"Pituitary"},{"key":"614_CR8","doi-asserted-by":"crossref","first-page":"623","DOI":"10.1210\/er.2001-0022","volume":"23","author":"JJ Kopchick","year":"2002","unstructured":"Kopchick JJ, Parkinson C, Stevens EC, Trainer PJ (2002) Growth hormone receptor antagonists: discovery, development, and use in patients with acromegaly. Endocr Rev 23:623\u2013646","journal-title":"Endocr Rev"},{"key":"614_CR9","doi-asserted-by":"crossref","first-page":"1754","DOI":"10.1016\/S0140-6736(01)06844-1","volume":"358","author":"AJ Lely van der","year":"2001","unstructured":"van der Lely AJ, Hutson RK, Trainer PJ et al (2001) Long-term treatment of acromegaly with pegvisomant, a growth hormone receptor antagonist. Lancet 358:1754\u20131759","journal-title":"Lancet"},{"key":"614_CR10","first-page":"2958","volume":"85","author":"VS Herman-Bonert","year":"2000","unstructured":"Herman-Bonert VS, Zib K, Scarlett JA, Melmed S (2000) Growth hormone receptor antagonist therapy in acromegalic patients resistant to somatostatin analogs. J Clin Endocrinol Metab 85:2958\u20132961","journal-title":"J Clin Endocrinol Metab"},{"key":"614_CR11","doi-asserted-by":"crossref","first-page":"451","DOI":"10.1530\/eje.0.1450451","volume":"145","author":"WM Drake","year":"2001","unstructured":"Drake WM, Parkinson C, Akker SA, Monson JP, Besser GM, Trainer PJ (2001) Successful treatment of resistant acromegaly with a growth hormone receptor antagonist. Eur J Endocrinol 145:451\u2013456","journal-title":"Eur J Endocrinol"},{"key":"614_CR12","doi-asserted-by":"crossref","first-page":"E265","DOI":"10.25011\/cim.v32i6.10662","volume":"32","author":"S Ezzat","year":"2009","unstructured":"Ezzat S, Gaspo R, Serri O, Ur E, Chik CL (2009) A Canadian multi-centre, open-label long-term study of Pegvisomant treatment in refractory acromegaly. Clin Invest Med 32:E265","journal-title":"Clin Invest Med"},{"key":"614_CR13","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1111\/j.1365-2265.2008.03469.x","volume":"71","author":"CE Higham","year":"2009","unstructured":"Higham CE, Chung TT, Lawrance J, Drake WM, Trainer PJ (2009) Long-term experience of pegvisomant therapy as a treatment for acromegaly. Clin Endocrinol 71:86\u201391","journal-title":"Clin Endocrinol"},{"key":"614_CR14","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1530\/eje.1.02312","volume":"156","author":"I Schreiber","year":"2007","unstructured":"Schreiber I, Buchfelder M, Droste M, Forssmann K, Mann K, Saller B, Strasburger CJ, German Pegvisomant Investigators (2007) Treatment of acromegaly with the GH receptor antagonist pegvisomant in clinical practice: safety and efficacy evaluation from the German Pegvisomant Observational Study. Eur J Endocrinol 156:75\u201382","journal-title":"Eur J Endocrinol"},{"issue":"Suppl 1","key":"614_CR15","doi-asserted-by":"crossref","first-page":"S19","DOI":"10.1530\/EJE-09-0322","volume":"161","author":"PJ Trainer","year":"2009","unstructured":"Trainer PJ (2009) ACROSTUDY: the first 5 years. Eur J Endocrinol 161(Suppl 1):S19\u2013S24","journal-title":"Eur J Endocrinol"},{"issue":"Suppl 1","key":"614_CR16","doi-asserted-by":"crossref","first-page":"S3","DOI":"10.1530\/EJE-09-0350","volume":"161","author":"M Buchfelder","year":"2009","unstructured":"Buchfelder M, Schlaffer S, Droste M, Mann K, Saller B, Br\u00fcbach K, Stalla GK, Strasburger CJ, German Pegvisomant Observational Study (2009) The German ACROSTUDY: past and present. Eur J Endocrinol 161(Suppl 1):S3\u2013S10.","journal-title":"Eur J Endocrinol"},{"key":"614_CR17","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1159\/000318493","volume":"38","author":"N Garc\u00eda Basavilbaso","year":"2010","unstructured":"Garc\u00eda Basavilbaso N, Guitelman M, Nagelberg A et al (2010) Experience from the Argentine Pegvisomant Observational Study: preliminary data. Front Horm Res 38:42\u201349","journal-title":"Front Horm Res"},{"key":"614_CR18","doi-asserted-by":"crossref","first-page":"883","DOI":"10.1111\/cen.12440","volume":"81","author":"G Sesmilo","year":"2014","unstructured":"Sesmilo G, Resmini E, Bernabeu I et al (2014) Escape and lipodystrophy in acromegaly during pegvisomant therapy, a retrospective multicentre Spanish study. Clin Endocrinol 81:883\u2013890","journal-title":"Clin Endocrinol"},{"issue":"2","key":"614_CR19","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1530\/EJE-09-0372","volume":"161","author":"A Giustina","year":"2009","unstructured":"Giustina A, Bonadonna S, Bugari G et al (2009) High-dose intramuscular octreotide in patients with acromegaly inadequately controlled on conventional somatostatin analogue therapy: a randomised controlled trial. Eur J Endocrinol 161(2):331\u2013338","journal-title":"Eur J Endocrinol"},{"issue":"2","key":"614_CR20","doi-asserted-by":"crossref","first-page":"E165","DOI":"10.1210\/jc.2011-1769","volume":"97","author":"M Filopanti","year":"2012","unstructured":"Filopanti M, Olgiati L, Mantovani G et al (2012) Growth hormone receptor variants and response to pegvisomant in monotherapy or in combination with somatostatin analogs in acromegalic patients: a multicenter study. J Clin Endocrinol Metab 97(2):E165\u2013E172","journal-title":"J Clin Endocrinol Metab"},{"issue":"8","key":"614_CR21","doi-asserted-by":"crossref","first-page":"693","DOI":"10.1007\/BF03347452","volume":"30","author":"A Colao","year":"2007","unstructured":"Colao A, Arnaldi G, Beck-Peccoz P et al (2007) Pegvisomant in acromegaly: why, when, how. J Endocrinol Invest 30(8):693\u2013699","journal-title":"J Endocrinol Invest"},{"key":"614_CR22","doi-asserted-by":"crossref","first-page":"555","DOI":"10.1373\/clinchem.2010.150631","volume":"57","author":"DR Clemmons","year":"2011","unstructured":"Clemmons DR (2011) Consensus statement on the standardization and evaluation of growth hormone and insulin-like growth factor assays. Clin Chem 57:555\u2013559","journal-title":"Clin Chem"},{"issue":"9","key":"614_CR23","doi-asserted-by":"crossref","first-page":"820","DOI":"10.1007\/BF03349263","volume":"31","author":"A Giustina","year":"2008","unstructured":"Giustina A, Barkan A, Chanson P et al (2008) Guidelines for the treatment of growth hormone excess and growth hormone deficiency in adults. J Endocrinol Invest 31(9):820\u2013838","journal-title":"J Endocrinol Invest"},{"key":"614_CR24","doi-asserted-by":"crossref","first-page":"1171","DOI":"10.1056\/NEJM200004203421604","volume":"342","author":"PJ Trainer","year":"2000","unstructured":"Trainer PJ, Drake WM, Katznelson L et al (2000) Treatment of acromegaly with the growth hormone-receptor antagonist pegvisomant. N Engl J Med 342:1171\u20131177","journal-title":"N Engl J Med"},{"key":"614_CR25","doi-asserted-by":"crossref","first-page":"549","DOI":"10.1111\/j.1365-2265.2009.03620.x","volume":"71","author":"PJ Trainer","year":"2009","unstructured":"Trainer PJ, Ezzat S, D\u2019Souza GA, Layton G, Strasburger CJ (2009) A randomized, controlled, multicentre trial comparing pegvisomant alone with combination therapy of PEG and long-acting octreotide in patients with acromegaly. Clin Endocrinol 71:549\u2013557","journal-title":"Clin Endocrinol"},{"key":"614_CR26","doi-asserted-by":"crossref","first-page":"1589","DOI":"10.1210\/jc.2011-2508","volume":"97","author":"AJ Lely van der","year":"2012","unstructured":"van der Lely AJ, Biller BMK, Brue T et al (2012) Long-Term safety of pegvisomant in patients with acromegaly: Comprehensive review of 1288 subjects in ACROSTUDY. J Clin Endocrinol Metab 97:1589\u20131597","journal-title":"J Clin Endocrinol Metab"},{"key":"614_CR27","doi-asserted-by":"crossref","first-page":"334","DOI":"10.1007\/s12020-014-0393-9","volume":"48","author":"S Grottoli","year":"2015","unstructured":"Grottoli S, Maffei P, Bogazzi F et al (2015) ACROSTUDY: the Italian experience. Endocr 48:334\u2013341","journal-title":"Endocr"},{"key":"614_CR28","doi-asserted-by":"crossref","first-page":"916","DOI":"10.1007\/s11102-015-0673-2","volume":"18","author":"C Sievers","year":"2015","unstructured":"Sievers C, Baur DM, Schwanke A et al (2015) Prediction of therapy response in acromegalic patients under pegvisomant therapy within the German ACROSTUDY cohort. Pituitary 18:916\u2013923","journal-title":"Pituitary"},{"key":"614_CR29","doi-asserted-by":"crossref","first-page":"1017","DOI":"10.1007\/s40618-014-0146-x","volume":"37","author":"A Giustina","year":"2014","unstructured":"Giustina A, Ambrosio MR, Beck Peccoz P et al (2014) Use of pegvisomant in acromegaly. An Italian Society of Endocrinology guideline. J Endocrinol Invest 37:1017\u20131130","journal-title":"J Endocrinol Invest"},{"key":"614_CR30","doi-asserted-by":"crossref","first-page":"1099","DOI":"10.1007\/s40618-015-0289-4","volume":"38","author":"S Cannav\u00f2","year":"2015","unstructured":"Cannav\u00f2 S, Bogazzi F, Colao A, the \u201cItalian Acrostudy Group\u201d et al (2015) Does pegvisomant treatment expertise improve control of resistant acromegaly? The Italian ACROSTUDY experience. J Endocrinol Invest 38:1099\u20131109","journal-title":"J Endocrinol Invest"},{"key":"614_CR31","doi-asserted-by":"crossref","first-page":"467","DOI":"10.1530\/eje.1.02112","volume":"154","author":"A Colao","year":"2006","unstructured":"Colao A, Pivonello R, Auriemma RS et al (2006) Efficacy of 12-month treatment with the GH receptor antagonist pegvisomant in patients with acromegaly resistant to long-term, high-dose somatostatin analog treatment: effect on IGF-I levels, tumor mass, hypertension and glucose tolerance. Eur J Endocrinol 154:467\u2013477","journal-title":"Eur J Endocrinol"},{"key":"614_CR32","doi-asserted-by":"crossref","first-page":"190","DOI":"10.1210\/jc.2006-1412","volume":"92","author":"C Parkinson","year":"2007","unstructured":"Parkinson C, Burman P, Messig M, Trainer PJ (2007) Gender, body weight, disease activity, and previous radiotherapy influence the response to pegvisomant. J Clin Endocrinol Metab 92:190\u2013195","journal-title":"J Clin Endocrinol Metab"},{"key":"614_CR33","doi-asserted-by":"crossref","first-page":"535","DOI":"10.1530\/EJE-08-0705","volume":"160","author":"M Marazuela","year":"2006","unstructured":"Marazuela M, Lucas T, Alvarez-Escol\u00e0 C et al (2006) Long-term treatment of acromegalic patients resistant to somatostatin analogues with the GH receptor antagonist pegvisomant: its efficacy in relation to gender and previous radiotherapy. Eur J Endocrinol 160:535\u2013542","journal-title":"Eur J Endocrinol"},{"issue":"4","key":"614_CR34","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1530\/EJE-16-0008","volume":"175","author":"AJ Lely van der","year":"2016","unstructured":"van der Lely AJ, Jonsson PJ, Wilton P, Akerblak AC, Ghigo EG (2016) Treatment with high doses of pegvisomant in 56 patients with acromegaly: experience from ACROSTUDY. Eur J Endocrinol 175(4):239\u2013245","journal-title":"Eur J Endocrinol"},{"key":"614_CR35","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1530\/EJE-13-0438","volume":"171","author":"M Droste","year":"2014","unstructured":"Droste M, Domberg J, Buchfelder M et al (2014) Therapy of acromegalic patients exacerbated by concomitant type 2 diabetes requires higher pegvisomant doses to normalise IGF-I levels. Eur J Endocrinol 171:59\u201368","journal-title":"Eur J Endocrinol"},{"key":"614_CR36","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1016\/j.ghir.2011.03.004","volume":"21","author":"SJ Neggers","year":"2011","unstructured":"Neggers SJ, van der Lely AJ (2011) Combination treatment with somatostatin analogues and PEG in acromegaly. Growth Horm IGF Res 21:129\u2013133","journal-title":"Growth Horm IGF Res"},{"key":"614_CR37","doi-asserted-by":"crossref","first-page":"196","DOI":"10.1007\/s11102-008-0157-8","volume":"12","author":"A Bianchi","year":"2009","unstructured":"Bianchi A, Mazziotti G, Tilaro L et al (2009) Growth hormone receptor polymorphism and the effects of pegvisomant in acromegaly. Pituitary 12:196\u2013199","journal-title":"Pituitary"},{"key":"614_CR38","doi-asserted-by":"crossref","first-page":"222","DOI":"10.1210\/jc.2009-1630","volume":"95","author":"I Bernabeu","year":"2010","unstructured":"Bernabeu I, Alvarez-Escol\u00e0 C, Quinteiro C et al (2010) The exon 3-deleted growth hormone receptor is associated with better response to pegvisomant therapy in acromegaly. J Clin Endocrinol Metab 95:222\u2013229","journal-title":"J Clin Endocrinol Metab"},{"key":"614_CR39","doi-asserted-by":"crossref","first-page":"553","DOI":"10.1530\/EJE-15-0519","volume":"173","author":"SE Franck","year":"2015","unstructured":"Franck SE, van der Lely AJ, Delhanty PJ, J\u00f8rgensen JO, Neggers SJ (2015) Pegvisomant in combination with long-acting somatostatin analogues in acromegaly: the role of the GH receptor deletion of exon 3. Eur J Endocrinol 173:553\u2013561","journal-title":"Eur J Endocrinol"},{"issue":"6","key":"614_CR40","doi-asserted-by":"crossref","first-page":"2015","DOI":"10.1210\/jc.2008-1337","volume":"94","author":"A Bianchi","year":"2009","unstructured":"Bianchi A, Giustina A, Cimino V, Pola R, Angelini F, Pontecorvi A, De Marinis L (2009) Influence of growth hormone receptor d3 and full-length isoforms on biochemical treatment outcomes in acromegaly. J Clin Endocrinol Metab 94(6):2015\u20132022","journal-title":"J Clin Endocrinol Metab"},{"key":"614_CR41","doi-asserted-by":"crossref","first-page":"666","DOI":"10.1007\/s11102-014-0629-y","volume":"18","author":"RS Jallad","year":"2015","unstructured":"Jallad RS, Trarbach EB, Duarte FH, Jorge AA, Bronstein MD (2015) Influence of growth hormone receptor (GHR) exon 3 and\u2014202A\/C IGFBP-3 genetic polymorphisms on clinical and biochemical features and therapeutic outcome of patients with acromegaly. Pituitary 18:666\u2013673","journal-title":"Pituitary"},{"key":"614_CR42","doi-asserted-by":"publisher","unstructured":"Franck SE, Broer L, van der Lely AJ et al (2016) The effect of the exon-3-deleted GH-receptor in pegvisomant-treated acromegaly: a systematic review and meta-analysis. Neuroendocrinology. doi: 10.1159\/000448844","DOI":"10.1159\/000448844"},{"key":"614_CR43","doi-asserted-by":"crossref","first-page":"E251","DOI":"10.1210\/jc.2010-1742","volume":"96","author":"M Marazuela","year":"2011","unstructured":"Marazuela M, Paniagua AE, Gahete MD et al (2011) Somatotroph tumor progression during pegvisomant therapy: a clinical and molecular study. J Clin Endocrinol Metab 96:E251\u2013E259","journal-title":"J Clin Endocrinol Metab"},{"issue":"2","key":"614_CR44","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1530\/eje.1.01968","volume":"153","author":"GM Besser","year":"2005","unstructured":"Besser GM, Burman P, Daly AF (2005) Predictors and rates of treatment-resistant tumor growth in acromegaly. Eur J Endocrinol 153(2):187\u2013193","journal-title":"Eur J Endocrinol"},{"key":"614_CR45","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1007\/s12020-014-0462-0","volume":"48","author":"A Giustina","year":"2015","unstructured":"Giustina A (2015) Optimal use of pegvisomant in acromegaly: are we getting there? Endocr 48:3\u20138","journal-title":"Endocr"},{"key":"614_CR46","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1186\/1756-9966-32-40","volume":"32","author":"A Bianchi","year":"2013","unstructured":"Bianchi A, Valentini F, Iuorio R et al (2013) Long-term treatment of somatostatin analog-refractory growth hormone-secreting pituitary tumors with pegvisomant alone or combined with long-acting somatostatin analogs: a retrospective analysis of clinical practice and outcomes. J Exp Clin Cancer Res 32:40","journal-title":"J Exp Clin Cancer Res"},{"key":"614_CR47","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1159\/000381644","volume":"103","author":"SJ Neggers","year":"2016","unstructured":"Neggers SJ, Muhammad A, van der Lely AJ (2016) Pegvisomant treatment in acromegaly. Neuroendocrinology 103:59\u201365","journal-title":"Neuroendocrinology"},{"key":"614_CR48","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1097\/MED.0b013e32836318a1","volume":"20","author":"M Fleseriu","year":"2013","unstructured":"Fleseriu M (2013) The role of combination medical therapy in acromegaly: hope for the nonresponsive patient. Curr Opin Endocrinol Diabetes Obes 20:321\u2013329","journal-title":"Curr Opin Endocrinol Diabetes Obes"},{"key":"614_CR49","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1016\/bs.pmbts.2015.10.015","volume":"138","author":"S Frara","year":"2016","unstructured":"Frara S, Maffezzoni F, Mazziotti G, Giustina A (2016) The modern criteria for medical management of acromegaly. Prog Mol Biol Transl Sci 138:63\u201383","journal-title":"Prog Mol Biol Transl Sci"},{"issue":"11","key":"614_CR50","doi-asserted-by":"crossref","first-page":"875","DOI":"10.1016\/S2213-8587(14)70169-X","volume":"2","author":"MR Gadelha","year":"2014","unstructured":"Gadelha MR, Bronstein MD, Brue T et al (2014) Pasireotide versus continued treatment with octreotide or lanreotide in patients with inadequately controlled acromegaly (PAOLA): a randomised, phase 3 trial. Lancet Diabetes Endocrinol 2(11):875\u2013884","journal-title":"Lancet Diabetes Endocrinol"},{"issue":"4","key":"614_CR51","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1038\/nrendo.2014.21","volume":"10","author":"A Giustina","year":"2014","unstructured":"Giustina A, Chanson P, Kleinberg D, Bronstein MD (2014) Expert consensus document: a consensus on the medical treatment of acromegaly. Nat Rev Endocrinol 10(4):243\u2013248","journal-title":"Nat Rev Endocrinol"},{"issue":"1","key":"614_CR52","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1111\/j.1365-2265.2009.03773.x","volume":"73","author":"C Sievers","year":"2010","unstructured":"Sievers C, Brubach K, Saller B et al (2010) Change of symptoms and perceived health in acromegalic patients on pegvisomant therapy: a retrospective cohort study within the German Pegvisomant Observational Study (GPOS). Clin Endocrinol (Oxf) 73(1):89\u201394","journal-title":"Clin Endocrinol (Oxf)"},{"issue":"4","key":"614_CR53","doi-asserted-by":"crossref","first-page":"411","DOI":"10.1530\/EJE-07-0356","volume":"157","author":"G T\u2019Sjoen","year":"2007","unstructured":"T\u2019Sjoen G, Bex M, Maiter D, Velkeniers B, Abs R (2007) Health-related quality of life in acromegalic subjects: data from AcroBel, the Belgian registry on acromegaly. Eur J Endocrinol 157(4):411\u2013417","journal-title":"Eur J Endocrinol"},{"issue":"2","key":"614_CR54","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1046\/j.1365-2265.2002.01597.x","volume":"57","author":"SM Webb","year":"2002","unstructured":"Webb SM, Prieto L, Badia X et al (2002) Acromegaly Quality of Life Questionnaire (ACROQOL) a new health-related quality of life questionnaire for patients with acromegaly: development and psychometric properties. Clin Endocrinol (Oxf) 57(2):251\u2013258","journal-title":"Clin Endocrinol (Oxf)"},{"issue":"3","key":"614_CR55","doi-asserted-by":"crossref","first-page":"305","DOI":"10.1530\/EJE-07-0697","volume":"158","author":"MP Matta","year":"2008","unstructured":"Matta MP, Couture E, Cazals L et al (2008) Impaired quality of life of patients with acromegaly: control of GH\/IGF-I excess improves psychological subscale appearance. Eur J Endocrinol 158(3):305\u2013310","journal-title":"Eur J Endocrinol"},{"issue":"6","key":"614_CR56","doi-asserted-by":"crossref","first-page":"495","DOI":"10.1007\/s11102-013-0533-x","volume":"17","author":"R Mangupli","year":"2014","unstructured":"Mangupli R, Camperos P, Webb SM (2014) Biochemical and quality of life responses to octreotide-LAR in acromegaly. Pituitary 17(6): 495\u2013499","journal-title":"Pituitary"},{"issue":"11","key":"614_CR57","doi-asserted-by":"crossref","first-page":"924","DOI":"10.1007\/BF03345774","volume":"32","author":"E Ghigo","year":"2009","unstructured":"Ghigo E, Biller BM, Colao A et al (2009) Comparison of pegvisomant and long-acting octreotide in patients with acromegaly na\u00efve to radiation and medical therapy. J Endocrinol Invest 32(11):924\u2013933","journal-title":"J Endocrinol Invest"},{"issue":"6","key":"614_CR58","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1007\/s11102-013-0544-7","volume":"17","author":"H Kepicoglu","year":"2014","unstructured":"Kepicoglu H, Hatipoglu E, Bulut I, Darici E, Hizli N, Kadioglu P (2014) Impact of treatment satisfaction on quality of life of patients with acromegaly. Pituitary 17(6):557\u2013563","journal-title":"Pituitary"},{"issue":"8","key":"614_CR59","doi-asserted-by":"crossref","first-page":"2405","DOI":"10.1210\/jc.2011-0654","volume":"96","author":"M Madsen","year":"2011","unstructured":"Madsen M, Poulsen PL, Orskov H et al (2011) Cotreatment with pegvisomant and a somatostatin analog (SSA) in SSA-responsive acromegalic patients. J Clin Endocrinol Metab 96(8):2405\u20132413","journal-title":"J Clin Endocrinol Metab"},{"issue":"1","key":"614_CR60","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1530\/EJE-08-0990","volume":"161","author":"CE Higham","year":"2009","unstructured":"Higham CE, Thomas JD, Bidlingmaier M et al (2009) Successful use of weekly pegvisomant administration in patients with acromegaly. Eur J Endocrinol 161(1):21\u201325","journal-title":"Eur J Endocrinol"},{"issue":"10","key":"614_CR61","doi-asserted-by":"crossref","first-page":"3644","DOI":"10.1210\/jc.2014-2032","volume":"99","author":"SJ Neggers","year":"2014","unstructured":"Neggers SJ, Franck SE, de Rooij FW et al (2014) Long-term efficacy and safety of pegvisomant in combination with long-acting somatostatin analogs in acromegaly. J Clin Endocrinol Metab 99(10):3644\u20133652","journal-title":"J Clin Endocrinol Metab"},{"issue":"4","key":"614_CR62","doi-asserted-by":"crossref","first-page":"256","DOI":"10.1016\/j.clindermatol.2006.04.011","volume":"24","author":"A Ben-Shlomo","year":"2006","unstructured":"Ben-Shlomo A, Melmed S (2006) Skin manifestations in acromegaly. Clin Dermatol 24(4):256\u2013259","journal-title":"Clin Dermatol"},{"issue":"1","key":"614_CR63","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1210\/er.2002-0022","volume":"25","author":"A Colao","year":"2004","unstructured":"Colao A, Ferone D, Marzullo P, Lombardi G (2004) Systemic complications of acromegaly: epidemiology, pathogenesis, and management. Endocr Rev 25(1):102\u2013152","journal-title":"Endocr Rev"},{"issue":"1","key":"614_CR64","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1159\/000375450","volume":"103","author":"KM Claessen","year":"2016","unstructured":"Claessen KM, Mazziotti G, Biermasz NR, Giustina A (2016) Bone and joint disorders in acromegaly. Neuroendocrinology 103(1):86\u201395","journal-title":"Neuroendocrinology"},{"issue":"10","key":"614_CR65","doi-asserted-by":"crossref","first-page":"919","DOI":"10.1007\/BF03346442","volume":"31","author":"A Giustina","year":"2008","unstructured":"Giustina A, Gola M, Colao A et al (2008) The management of the patient with acromegaly and headache: a still open clinical challenge. J Endocrinol Invest 31(10):919\u2013924","journal-title":"J Endocrinol Invest"},{"issue":"3","key":"614_CR66","doi-asserted-by":"crossref","first-page":"1000","DOI":"10.1158\/1078-0432.CCR-06-1910","volume":"13","author":"D Yin","year":"2007","unstructured":"Yin D, Vreeland F, Schaaf LJ, Millham R, Duncan BA, Sharma A (2007) Clinical pharmacodynamic effects of the growth hormone receptor antagonist pegvisomant: implications for cancer therapy. Clin Cancer Res 13(3):1000\u20131009","journal-title":"Clin Cancer Res"},{"issue":"3","key":"614_CR67","doi-asserted-by":"crossref","first-page":"294","DOI":"10.1007\/s11102-012-0420-x","volume":"16","author":"S Melmed","year":"2013","unstructured":"Melmed S, Casanueva FF, Klibanski A et al (2013) A consensus on the diagnosis and treatment of acromegaly complications. Pituitary 16(3):294\u2013302","journal-title":"Pituitary"},{"issue":"3","key":"614_CR68","doi-asserted-by":"crossref","first-page":"433","DOI":"10.1007\/s00592-014-0635-6","volume":"52","author":"A Giustina","year":"2015","unstructured":"Giustina A, Berardelli R, Gazzaruso C, Mazziotti G (2015) Insulin and GH-IGF-I axis: endocrine pacer or endocrine disruptor? Acta Diabetol 52(3):433\u2013443","journal-title":"Acta Diabetol"},{"key":"614_CR69","doi-asserted-by":"crossref","first-page":"1500","DOI":"10.1210\/jc.2008-2332","volume":"94","author":"G Mazziotti","year":"2009","unstructured":"Mazziotti G, Floriani I, Bonadonna S, Torri V, Chanson P, Giustina A (2009) Effects of somatostatin analogs on glucose homeostasis: a metaanalysis of acromegaly studies. J Clin Endocrinol Metab 94:1500\u20131508","journal-title":"J Clin Endocrinol Metab"},{"key":"614_CR70","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1530\/EJE-10-0811","volume":"164","author":"G Mazziotti","year":"2011","unstructured":"Mazziotti G, Porcelli T, Bogazzi F et al (2011) Effects of high-dose octreotide LAR on glucose metabolism in patients with acromegaly inadequately controlled by conventional somatostatin analog therapy. Eur J Endocrinol 164:341\u2013347","journal-title":"Eur J Endocrinol"},{"key":"614_CR71","doi-asserted-by":"crossref","first-page":"1619","DOI":"10.1517\/13543784.2014.942728","volume":"23","author":"A Giustina","year":"2014","unstructured":"Giustina A, Mazziotti G, Maffezzoni F, Amoroso V, Berruti A (2014) Investigational drugs targeting somatostatin receptors for treatment of acromegaly and neuroendocrine tumors. Expert Opin Investig Drugs 23:1619\u20131635","journal-title":"Expert Opin Investig Drugs"},{"issue":"7","key":"614_CR72","doi-asserted-by":"crossref","first-page":"470","DOI":"10.1016\/j.tem.2016.04.014","volume":"27","author":"S Frara","year":"2016","unstructured":"Frara S, Maffezzoni F, Mazziotti G, Giustina A (2016)\u00a0Current and emerging aspects of diabetes mellitus in acromegaly.\u00a0Trends Endocrinol Metab\u00a027(7):470\u2013483","journal-title":"Trends Endocrinol Metab"},{"issue":"1","key":"614_CR73","first-page":"210","volume":"53","author":"HA Schmid","year":"2016","unstructured":"Schmid HA, Brue T, Colao A et al (2016) Effect of pasireotide on glucose- and growth hormone-related biomarkers in patients with inadequately controlled acromegaly. Endocrine 2016 53(1):210\u2013219","journal-title":"Endocrine 2016"},{"key":"614_CR74","doi-asserted-by":"crossref","first-page":"470","DOI":"10.1016\/j.tem.2016.04.014","volume":"27","author":"S Frara","year":"2016","unstructured":"Frara S, Maffezzoni F, Mazziotti G, Giustina A (2016) Current and emerging aspects of diabetes mellitus in acromegaly. Trends Endocrinol Metab 27:470\u2013483","journal-title":"Trends Endocrinol Metab"},{"key":"614_CR75","doi-asserted-by":"crossref","first-page":"2459","DOI":"10.1210\/jc.2008-2086","volume":"94","author":"CE Higham","year":"2009","unstructured":"Higham CE, Rowles S, Russell-Jones D, Umpleby AM, Trainer PJ (2009) Pegvisomant improves sensitivity and reduces overnight free fatty acid concentrations in patients with acromegaly. J Clin Endocrinol Metab 94:2459\u20132463","journal-title":"J Clin Endocrinol Metab"},{"key":"614_CR76","doi-asserted-by":"crossref","first-page":"521","DOI":"10.1530\/eje.0.1490521","volume":"149","author":"WM Drake","year":"2003","unstructured":"Drake WM, Rowles SV, Roberts ME et al (2003) Insulin sensitivity and glucose tolerance improve in patients with acromegaly converted from depot octreotide to pegvisomant. Eur J Endocrinol 149:521\u2013527","journal-title":"Eur J Endocrinol"},{"key":"614_CR77","doi-asserted-by":"crossref","first-page":"5684","DOI":"10.1210\/jc.2005-0331","volume":"90","author":"AL Barkan","year":"2005","unstructured":"Barkan AL, Burman P, Clemmons DR et al (2005) Glucose homeostasis and safety in patients with acromegaly converted from long-acting octreotide to pegvisomant. J Clin Endocrinol Metab 90:5684\u20135691","journal-title":"J Clin Endocrinol Metab"},{"key":"614_CR78","doi-asserted-by":"crossref","first-page":"467","DOI":"10.1530\/EJE-07-0637","volume":"158","author":"U Pl\u00f6ckinger","year":"2008","unstructured":"Pl\u00f6ckinger U, Reuter T (2008) Pegvisomant increases intra-abdominal fat in patients with acromegaly: a pilot study. Eur J Endocrinol 158:467\u2013471","journal-title":"Eur J Endocrinol"},{"key":"614_CR79","doi-asserted-by":"crossref","first-page":"1724","DOI":"10.1210\/jc.2006-2276","volume":"92","author":"R Lindberg-Larsen","year":"2007","unstructured":"Lindberg-Larsen R, M\u00f8ller N, Schmitz O et al (2007) The impact of pegvisomant treatment on substrate metabolism and insulin sensitivity in patients with acromegaly. J Clin Endocrinol Metab 92:1724\u20131728","journal-title":"J Clin Endocrinol Metab"},{"key":"614_CR80","doi-asserted-by":"crossref","first-page":"418","DOI":"10.1016\/S1096-6374(02)00083-7","volume":"12","author":"DR Rose","year":"2002","unstructured":"Rose DR, Clemmons DR (2002) Growth hormone receptor antagonist improves insulin resistance in acromegaly. Growth Horm IGF Res 12:418\u2013424","journal-title":"Growth Horm IGF Res"},{"issue":"5","key":"614_CR81","doi-asserted-by":"crossref","first-page":"693","DOI":"10.1530\/EJE-15-0500","volume":"173","author":"E Kuhn","year":"2015","unstructured":"Kuhn E, Maione L, Bouchachi A et al (2015) Long-term effects of pegvisomant on comorbidities in patients with acromegaly: a retrospective single-center study. Eur J Endocrinol 173(5):693\u2013702","journal-title":"Eur J Endocrinol"},{"key":"614_CR82","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1210\/jc.2005-1704","volume":"91","author":"CL Ronchi","year":"2006","unstructured":"Ronchi CL, Varca V, Beck-Peccoz P et al (2006) Comparison between six-year therapy with long-acting somatostatin analogs and successful surgery in acromegaly: effects on cardiovascular risk factors. J Clin Endocrinol Metab 91:121\u2013128","journal-title":"J Clin Endocrinol Metab"},{"key":"614_CR83","doi-asserted-by":"crossref","first-page":"4124","DOI":"10.1210\/jc.2014-2259","volume":"99","author":"C Reyes-Vidal","year":"2014","unstructured":"Reyes-Vidal C, Fernandez JC, Bruce JN, Crisman C, Conwell IM, Kostadinov J, Geer EB, Post KD, Freda PU (2014) Prospective study of surgical treatment of acromegaly: effects on ghrelin, weight, adiposity, and markers of CV risk. J Clin Endocrinol Metab 99:4124\u20134132","journal-title":"J Clin Endocrinol Metab"},{"key":"614_CR84","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1111\/j.1365-2362.1993.tb00762.x","volume":"23","author":"RJ Brummer","year":"1993","unstructured":"Brummer RJ, Lonn L, Kvist H, Grangard U, Bengtsson BA, Sjostrom L (1993) Adipose tissue and muscle volume determination by computed tomography in acromegaly, before and 1\u00a0year after adenomectomy. Eur J Clin Invest 23:199\u2013205","journal-title":"Eur J Clin Invest"},{"key":"614_CR85","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1530\/eje.0.1480193","volume":"148","author":"ML Jaffrain-Rea","year":"2003","unstructured":"Jaffrain-Rea ML, Minniti G, Moroni C et al (2003) Impact of successful transsphenoidal surgery on cardiovascular risk factors in acromegaly. Eur J Endocrinol 148:193\u2013201","journal-title":"Eur J Endocrinol"},{"key":"614_CR86","doi-asserted-by":"crossref","first-page":"168","DOI":"10.1046\/j.1365-2265.2003.01795.x","volume":"59","author":"C Parkinson","year":"2003","unstructured":"Parkinson C, Whatmore AJ, Yates AP, Drake WM, Brabant G, Clayton PE, Trainer PJ (2003) The effect of pegvisomant-induced serum IGF-I normalization on serum leptin levels in patients with acromegaly. Clin Endocrinol 59:168\u2013174","journal-title":"Clin Endocrinol"},{"key":"614_CR87","doi-asserted-by":"crossref","first-page":"136","DOI":"10.1007\/s11102-008-0104-8","volume":"12","author":"L Katznelson","year":"2009","unstructured":"Katznelson L (2009) Alterations in body composition in acromegaly. Pituitary 12:136\u2013142","journal-title":"Pituitary"},{"issue":"1","key":"614_CR88","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1007\/BF03346696","volume":"34","author":"E Menis De","year":"2011","unstructured":"De Menis E, Giustina A, Colao A et al (2011) Assessment of the awareness and management of sleep apnea syndrome in acromegaly. The COM.E.TA (Comorbidities Evaluation and Treatment in Acromegaly) Italian Study Group. J Endocrinol Invest 34(1):60\u201364","journal-title":"J Endocrinol Invest"},{"key":"614_CR89","doi-asserted-by":"crossref","first-page":"649","DOI":"10.1111\/j.1365-2265.1987.tb02947.x","volume":"27","author":"T Pekkarinen","year":"1987","unstructured":"Pekkarinen T, Partinen M, Pelkonen R, Iivanainen M (1987) Sleep apnoea and daytime sleepiness in acromegaly: relationship to endocrinological factors. Clin Endocrinol 27:649\u2013654","journal-title":"Clin Endocrinol"},{"key":"614_CR90","doi-asserted-by":"crossref","first-page":"533","DOI":"10.1530\/EJE-08-0442","volume":"159","author":"MV Davi","year":"2008","unstructured":"Davi MV, Dalle Carbonare L, Giustina A et al (2008) Sleep apnoea syndrome is highly prevalent in acromegaly and only partially reversible after biochemical control of the disease. Eur J Endocrinol 159:533\u2013540","journal-title":"Eur J Endocrinol"},{"key":"614_CR91","doi-asserted-by":"crossref","first-page":"563","DOI":"10.1046\/j.1365-2265.1996.00852.x","volume":"45","author":"F Rosenow","year":"1996","unstructured":"Rosenow F, Reuter S, Deuss U et al (1996) Sleep apnoea in treated acromegaly: relative frequency and predisposing factors. Clin Endocrinol 45:563\u2013569","journal-title":"Clin Endocrinol"},{"key":"614_CR92","doi-asserted-by":"crossref","first-page":"1247","DOI":"10.1007\/s11325-011-0641-7","volume":"16","author":"J Roemmler","year":"2012","unstructured":"Roemmler J, Gutt B, Fischer R et al (2012) Elevated incidence of sleep apnoea in acromegaly-correlation to disease activity. Sleep Breath 16:1247\u20131253","journal-title":"Sleep Breath"},{"key":"614_CR93","doi-asserted-by":"crossref","first-page":"527","DOI":"10.7326\/0003-4819-115-7-527","volume":"115","author":"RR Grunstein","year":"1991","unstructured":"Grunstein RR, Ho KY, Sullivan CE (1991) Sleep apnea in acromegaly. Ann Intern Med 115:527\u2013532","journal-title":"Ann Intern Med"},{"key":"614_CR94","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1530\/eje.0.1510309","volume":"151","author":"BL Herrmann","year":"2004","unstructured":"Herrmann BL, Wessendorf TE, Ajaj W, Kahlke S, Teschler H, Mann K (2004) Effects of octreotide on sleep apnoea and tongue volume (magnetic resonance imaging) in patients with acromegaly. Eur J Endocrinol 151:309\u2013315","journal-title":"Eur J Endocrinol"},{"key":"614_CR95","doi-asserted-by":"crossref","first-page":"477","DOI":"10.1046\/j.1365-2265.2001.01358.x","volume":"55","author":"MS Ip","year":"2001","unstructured":"Ip MS, Tan KC, Peh WC, Lam KS (2001) Effect of Sandostatin LAR on sleep apnoea in acromegaly: correlation with computerized tomographic cephalometry and hormonal activity. Clin Endocrinol 55:477\u2013483","journal-title":"Clin Endocrinol"},{"key":"614_CR96","doi-asserted-by":"crossref","first-page":"829","DOI":"10.1530\/EJE-09-0694","volume":"161","author":"C Berg","year":"2009","unstructured":"Berg C, Wessendorf TE, Mortsch F et al (2009) Influence of disease control with pegvisomant on sleep apnoea and tongue volume in patients with active acromegaly. Eur J Endocrinol 161:829\u2013835","journal-title":"Eur J Endocrinol"},{"key":"614_CR97","doi-asserted-by":"crossref","first-page":"4649","DOI":"10.1210\/jc.2008-0791","volume":"93","author":"G Mazziotti","year":"2008","unstructured":"Mazziotti G, Bianchi A, Bonadonna S et al (2008) Prevalence of vertebral fractures in men with acromegaly. J Clin Endocrinol Metab 93:4649\u20134655","journal-title":"J Clin Endocrinol Metab"},{"key":"614_CR98","doi-asserted-by":"crossref","first-page":"1837","DOI":"10.1359\/JBMR.050603","volume":"20","author":"S Bonadonna","year":"2005","unstructured":"Bonadonna S, Mazziotti G, Nuzzo M et al (2005) Increased prevalence of radiological spinal deformities in active acromegaly: a cross-sectional study in postmenopausal women. J Bone Miner Res 20:1837\u20131844","journal-title":"J Bone Miner Res"},{"key":"614_CR99","doi-asserted-by":"crossref","first-page":"384","DOI":"10.1210\/jc.2014-2937","volume":"100","author":"G Mazziotti","year":"2015","unstructured":"Mazziotti G, Biagioli E, Maffezzoni F et al (2015) Bone turnover, bone mineral density, and fracture risk in acromegaly: a meta-analysis. J Clin Endocrinol Metab 100:384\u2013894","journal-title":"J Clin Endocrinol Metab"},{"key":"614_CR100","doi-asserted-by":"crossref","first-page":"5650","DOI":"10.1210\/jc.2003-030772","volume":"88","author":"C Parkinson","year":"2003","unstructured":"Parkinson C, Kassem M, Heickendorff L, Flyvbjerg A, Trainer PJ (2003) Pegvisomant-induced serum insulin-like growth factor-I normalization in patients with acromegaly returns elevated markers of bone turnover to normal. J Clin Endocrinol Metab 88:5650\u20135655","journal-title":"J Clin Endocrinol Metab"},{"key":"614_CR101","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1055\/s-0030-1268006","volume":"43","author":"C Jimenez","year":"2011","unstructured":"Jimenez C, Ayala-Ramirez M, Liu J, Nunez R, Gagel RF (2011) Inhibition of growth hormone receptor activation by pegvisomant may increase bone density in acromegaly. Horm Metab Res 43:55\u201361","journal-title":"Horm Metab Res"},{"key":"614_CR102","doi-asserted-by":"crossref","first-page":"3402","DOI":"10.1210\/jc.2013-1460","volume":"98","author":"G Mazziotti","year":"2013","unstructured":"Mazziotti G, Bianchi A, Porcelli T et al (2013) Vertebral fractures in patients with acromegaly: a 3-year prospective study. J Clin Endocrinol Metab 98:3402\u20133410","journal-title":"J Clin Endocrinol Metab"},{"key":"614_CR103","doi-asserted-by":"crossref","first-page":"310","DOI":"10.7326\/0003-4819-145-4-200608150-00017","volume":"145","author":"P Maffei","year":"2006","unstructured":"Maffei P, Martini C, Pagano C, Sicolo N, Corbetti F (2006) Lipohypertrophy in acromegaly induced by the new growth hormone receptor antagonist PEG. Ann Intern Med 145:310\u2013312","journal-title":"Ann Intern Med"},{"key":"614_CR104","doi-asserted-by":"crossref","first-page":"741","DOI":"10.7326\/0003-4819-147-10-200711200-00019","volume":"147","author":"M Marazuela","year":"2007","unstructured":"Marazuela M, Daud\u00e9n E, Oc\u00f3n E, Moure D, Nattero L (2007) Pegvisomant-induced lipohypertrophy: report of a case with histopathology. Ann Intern Med 147:741\u2013743","journal-title":"Ann Intern Med"},{"key":"614_CR105","doi-asserted-by":"crossref","first-page":"3515","DOI":"10.1210\/jc.2008-0833","volume":"93","author":"VS Bonert","year":"2008","unstructured":"Bonert VS, Kennedy L, Petersenn S et al (2008) Lipodystrophy in patients with acromegaly receiving pegvisomant. J Clin Endocrinol Metab 93:3515\u20133518","journal-title":"J Clin Endocrinol Metab"},{"key":"614_CR106","doi-asserted-by":"crossref","first-page":"655","DOI":"10.1111\/j.1365-2265.2008.03400.x","volume":"70","author":"S Cannav\u00f2","year":"2009","unstructured":"Cannav\u00f2 S, Romanello G, Cavallari V, Scisca C, Cannavo SP (2009) Subcutaneous lipoatrophy induced by long-term pegvisomant administration. Clin Endocrinol (Oxf) 70:655\u2013656","journal-title":"Clin Endocrinol (Oxf)"},{"key":"614_CR107","doi-asserted-by":"crossref","first-page":"2731","DOI":"10.1210\/jcem.84.8.5858","volume":"84","author":"GA Kaltsas","year":"1999","unstructured":"Kaltsas GA, Mukherjee JJ, Jenkins PJ et al (1999) Menstrual irregularity in women with acromegaly. J Clin Endocrinol Metab 84:2731\u20132735","journal-title":"J Clin Endocrinol Metab"},{"key":"614_CR108","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1046\/j.1365-2265.2001.01214.x","volume":"54","author":"L Katznelson","year":"2001","unstructured":"Katznelson L, Kleinberg D, Vance ML et al (2001) Hypogonadism in patients with acromegaly: data from the multi-centre acromegaly registry pilot study. Clin Endocrinol (Oxf) 54:183\u2013188","journal-title":"Clin Endocrinol (Oxf)"},{"key":"614_CR109","doi-asserted-by":"crossref","first-page":"4518","DOI":"10.1210\/jc.2009-2815","volume":"95","author":"M Grynberg","year":"2010","unstructured":"Grynberg M, Salenave S, Young J, Chanson P (2010) Female gonadal function before and after treatment of acromegaly. J Clin Endocrinol Metab 95:4518\u20134525","journal-title":"J Clin Endocrinol Metab"},{"issue":"9138","key":"614_CR110","doi-asserted-by":"crossref","first-page":"1455","DOI":"10.1016\/S0140-6736(98)03356-X","volume":"352","author":"A Colao","year":"1998","unstructured":"Colao A, Lombardi G (1998) Growth-hormone and prolactin excess. Lancet 352(9138):1455\u20131461","journal-title":"Lancet"},{"key":"614_CR111","doi-asserted-by":"crossref","first-page":"917","DOI":"10.1111\/j.1365-2265.2007.02987.x","volume":"67","author":"GA Kaltsas","year":"2007","unstructured":"Kaltsas GA, Androulakis II, Tziveriotis K et al (2007) Polycystic ovaries and the polycystic ovary syndrome phenotype in women with active acromegaly. Clin Endocrinol (Oxf) 67:917\u2013922","journal-title":"Clin Endocrinol (Oxf)"},{"key":"614_CR112","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1007\/s40618-013-0019-8","volume":"37","author":"R Pivonello","year":"2014","unstructured":"Pivonello R, De Martino MC, Auriemma RS et al (2014) Pituitary tumors and pregnancy: the interplay between a pathologic condition and a physiologic status. J Endocrinol Invest 37:99\u2013112","journal-title":"J Endocrinol Invest"},{"key":"614_CR113","doi-asserted-by":"crossref","first-page":"264","DOI":"10.1111\/j.1365-2265.2011.04180.x","volume":"76","author":"S Cheng","year":"2012","unstructured":"Cheng S, Grasso L, Martinez-Orozco JA et al (2012) Pregnancy in acromegaly: experience from two referral centers and systematic review of the literature. Clin Endocrinol (Oxf) 76:264\u2013271","journal-title":"Clin Endocrinol (Oxf)"},{"key":"614_CR114","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1530\/EJE-13-0460","volume":"170","author":"M Dias","year":"2013","unstructured":"Dias M, Boguszewski C, Gadelha M et al (2013) Acromegaly and pregnancy: a prospective study. Eur J Endocrinol 170:301\u2013310","journal-title":"Eur J Endocrinol"},{"key":"614_CR115","doi-asserted-by":"crossref","first-page":"704","DOI":"10.1016\/j.jgyn.2013.04.008","volume":"3","author":"ML Persechini","year":"2014","unstructured":"Persechini ML, Gennero I, Grunenwald S et al (2014) Acromegaly and pregnancy: report of six new cases. J Gynecol Obstet Biol Reprod (Paris) 3:704\u2013712","journal-title":"J Gynecol Obstet Biol Reprod (Paris)"},{"key":"614_CR116","doi-asserted-by":"crossref","first-page":"4680","DOI":"10.1210\/jc.2009-2331","volume":"95","author":"P Caron","year":"2010","unstructured":"Caron P, Broussaud S, Bertherat J et al (2010) Acromegaly and pregnancy: a retrospective multicenter study of 59 pregnancies in 46 women. J Clin Endocrinol Metab 95:4680\u20134687","journal-title":"J Clin Endocrinol Metab"},{"key":"614_CR117","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1007\/s11102-011-0330-3","volume":"15","author":"V Cheng","year":"2012","unstructured":"Cheng V, Faiman C, Kennedy L et al (2012) Pregnancy and acromegaly: a review. Pituitary 15:59\u201363","journal-title":"Pituitary"},{"key":"614_CR118","doi-asserted-by":"crossref","first-page":"668","DOI":"10.1111\/j.1365-2265.2009.03706.x","volume":"72","author":"P Maffei","year":"2010","unstructured":"Maffei P, Tamagno G, Nardelli GB et al (2010) Effects of octreotide exposure during pregnancy in acromegaly. Clin Endocrinol (Oxf) 72:668\u2013677","journal-title":"Clin Endocrinol (Oxf)"},{"key":"614_CR119","doi-asserted-by":"crossref","first-page":"411","DOI":"10.1046\/j.1365-2265.2001.01304.x","volume":"55","author":"M Fassnacht","year":"2001","unstructured":"Fassnacht M, Capeller B, Arlt W, Steck T, Allolio B (2001) Octreotide LAR treatment throughout pregnancy in an acromegalic woman. Clin Endocrinol (Oxf) 55:411\u2013415","journal-title":"Clin Endocrinol (Oxf)"},{"key":"614_CR120","doi-asserted-by":"crossref","first-page":"439","DOI":"10.1007\/s10815-006-9077-6","volume":"23","author":"A Qureshi","year":"2006","unstructured":"Qureshi A, Kalu E, Ramanathan G et al (2006) IVF\/ICSI in a woman with active acromegaly: successful outcome following treatment with pegvisomant. J Assist Reprod Genet 23:439\u2013442","journal-title":"J Assist Reprod Genet"},{"key":"614_CR121","doi-asserted-by":"crossref","first-page":"3374","DOI":"10.1210\/jc.2007-0997","volume":"92","author":"SR Brian","year":"2007","unstructured":"Brian SR, Bidlingmaier M, Wajnrajch MP, Weinzimer SA, Inzucchi SE (2007) Treatment of acromegaly with pegvisomant during pregnancy: maternal and fetal effects. J Clin Endocrinol Metab 92:3374\u20133377","journal-title":"J Clin Endocrinol Metab"},{"key":"614_CR122","doi-asserted-by":"crossref","first-page":"769","DOI":"10.1007\/s12020-014-0508-3","volume":"49","author":"AJ Lely Van der","year":"2015","unstructured":"Van der Lely AJ, Gomez R, Heissler JF et al (2015) Pregnancy in acromegaly patients treated with pegvisomant. Endocr 49:769\u2013773","journal-title":"Endocr"},{"key":"614_CR123","doi-asserted-by":"crossref","first-page":"S87","DOI":"10.1053\/plac.2002.0811","volume":"23","author":"MC Lacroix","year":"2002","unstructured":"Lacroix MC, Guibourdenche J, Frendo JL, Muller F, Evain-Brion D (2002) Human placental growth hormone\u2014a review. Placenta 23:S87\u2013S94","journal-title":"Placenta"},{"key":"614_CR124","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1016\/S0303-7207(98)00040-9","volume":"140","author":"E Alsat","year":"1998","unstructured":"Alsat E, Guibourdenche J, Couturier A, Evain-Brion D (1998) Physiological role of human placental growth hormone. Mol Cell Endocrinol 140:121\u2013127","journal-title":"Mol Cell Endocrinol"},{"key":"614_CR125","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1111\/cen.12731","volume":"83","author":"M Puig Domingo","year":"2015","unstructured":"Puig Domingo M (2015) Treatment of acromegaly in the era of personalized and predictive medicine. Clin Endocrinol (Oxf) 83:3\u201314","journal-title":"Clin Endocrinol (Oxf)"},{"key":"614_CR126","doi-asserted-by":"crossref","first-page":"L25","DOI":"10.1530\/ERC-12-0020","volume":"19","author":"L Kasuki","year":"2012","unstructured":"Kasuki L, Vieira Neto L, Wildemberg LE et al (2012) AIP expression in sporadic somatotropinomas is a predictor of the response to octreotide LAR therapy independent of SSTR2 expression. Endocr Relat Cancer 19:L25\u2013L29","journal-title":"Endocr Relat Cancer"},{"key":"614_CR127","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1530\/ERC-15-0038","volume":"22","author":"A Beckers","year":"2015","unstructured":"Beckers A, Lodish MB, Trivellin G et al (2015) X-linked acrogigantism syndrome: clinical profile and therapeutic responses. Endocr Relat Cancer 22:353\u2013367","journal-title":"Endocr Relat Cancer"},{"key":"614_CR128","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1007\/BF03349183","volume":"29","author":"M Gola","year":"2006","unstructured":"Gola M, Bonadonna S, Mazziotti G, Amato G, Giustina A (2006) Resistance to somatostatin analogs in acromegaly: an evolving concept? J Endocrinol Invest 29:86\u201393","journal-title":"J Endocrinol Invest"},{"key":"614_CR129","doi-asserted-by":"crossref","first-page":"184","DOI":"10.1007\/s11102-010-0282-z","volume":"14","author":"M Fleseriu","year":"2011","unstructured":"Fleseriu M (2011) Clinical efficacy and safety results for dose escalation of somatostatin receptor ligands in patients with acromegaly: a literature review. Pituitary 14:184\u2013193","journal-title":"Pituitary"},{"issue":"2","key":"614_CR130","first-page":"526","volume":"85","author":"A Giustina","year":"2000","unstructured":"Giustina A, Barkan A, Casanueva FF et al (2000) Criteria for cure of acromegaly: a consensus statement. J Clin Endocrinol Metab 85(2):526\u2013529","journal-title":"J Clin Endocrinol Metab"},{"key":"614_CR131","doi-asserted-by":"crossref","first-page":"1397","DOI":"10.1210\/jc.2005-2347","volume":"91","author":"R Cozzi","year":"2006","unstructured":"Cozzi R, Montini M, Attanasio R et al (2006) Primary treatment of acromegaly with octreotide LAR: a long-term (up to nine years) prospective study of its efficacy in the control of disease activity and tumor shrinkage. J Clin Endocrinol Metab 91:1397\u20131403","journal-title":"J Clin Endocrinol Metab"},{"key":"614_CR132","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1111\/j.1365-2265.2009.03626.x","volume":"72","author":"TJ Reid","year":"2010","unstructured":"Reid TJ, Post KD, Bruce JN et al (2010) Features at diagnosis of 324 patients with acromegaly did not change from 1981 to 2006; acromegaly remains under-recognized and under-diagnosed. Clin Endocrinol (Oxf) 72:203\u2013208","journal-title":"Clin Endocrinol (Oxf)"}],"updated-by":[{"DOI":"10.1007\/s40618-017-0800-1","type":"correction","label":"Correction","source":"publisher","updated":{"date-parts":[[2017,12,28]],"date-time":"2017-12-28T00:00:00Z","timestamp":1514419200000}}],"container-title":["Journal of Endocrinological Investigation"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s40618-017-0614-1\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s40618-017-0614-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s40618-017-0614-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,6,22]],"date-time":"2024-06-22T06:19:00Z","timestamp":1719037140000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s40618-017-0614-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,2,7]]},"references-count":132,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2017,6]]}},"alternative-id":["614"],"URL":"https:\/\/doi.org\/10.1007\/s40618-017-0614-1","relation":{},"ISSN":["1720-8386"],"issn-type":[{"value":"1720-8386","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017,2,7]]}}}